<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; AngioDynamics Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/angiodynamics-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BSDM) BSD Medical Makes Classic Pact</title>
		<link>http://www.stockbloghub.com/2011/06/29/bsdm-bsd-medical-makes-classic-pact/77639</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bsdm-bsd-medical-makes-classic-pact/77639#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:54:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSD Medical Corporation]]></category>
		<category><![CDATA[BSDM]]></category>
		<category><![CDATA[BSX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77639</guid>
		<description><![CDATA[Cancer treatment systems maker BSD Medical Corp (BSDM) has forged an exclusive distribution pact with Classic Medical Inc. (Classic Medical) for its MicroThermX Microwave Ablation system for soft tissue ablation (destruction). Classic Medical is a leading distributor of minimally-invasive surgical products with a rich history of selling state-of-the-art surgical devices made by some of the major medical companies in the U.S. Moreover, the entity has long-term associations with doctors, key opinion leaders and hospitals across the Southeastern U.S. Classic Medical has a dedicated sales force specialized in marketing surgical products for the interventional radiology market, the target area for BSD Medical’s ablation products. The deal provides it the rights to distribute the MicroThermX products in North Carolina, South Carolina, Georgia, Florida, Alabama and Tennessee. The agreement concludes BSD Medical’s efforts ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bsdm-bsd-medical-makes-classic-pact/77639/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSDM) BSD Medical&#8217;s MicroThermX Gains Acceptance</title>
		<link>http://www.stockbloghub.com/2011/06/26/bsdm-bsd-medicals-microthermx-gains-acceptance/77413</link>
		<comments>http://www.stockbloghub.com/2011/06/26/bsdm-bsd-medicals-microthermx-gains-acceptance/77413#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:42:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSD Medical Corporation]]></category>
		<category><![CDATA[BSDM]]></category>
		<category><![CDATA[BSX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77413</guid>
		<description><![CDATA[Cancer treatment systems maker BSD Medical Corp. (BSDM) recently revealed acceptance of its MicroThermX Microwave Ablation System (“MicroThermX”) at the World Conference on Interventional Oncology (“WCIO”) convened in New York City, between June 9 and 12, 2011. The two technical presentations, showcasing the benefits of the MicroThermX system, were the cynosure of the WCIO convention. The WCIO gathering was attended by participants from across the globe. It concentrated on the usage of less invasive treatments for cancer. In this regard, the meeting focused on the usage of microwave ablation as the first-choice, minimally-invasive therapy for cancer. The meeting was graced by important opinion makers from across the globe. Two researchers from Brown University/Rhode Island Hospital provided testing information, as a part of the conference’s scientific presentations, showing that the unusual ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/bsdm-bsd-medicals-microthermx-gains-acceptance/77413/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) Company News for June 16, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/16/ango-company-news-for-june-16-2011-corporate-summary/76538</link>
		<comments>http://www.stockbloghub.com/2011/06/16/ango-company-news-for-june-16-2011-corporate-summary/76538#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:20:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[Ceradyne Inc.]]></category>
		<category><![CDATA[CRDN]]></category>
		<category><![CDATA[General Mills Inc.]]></category>
		<category><![CDATA[GIS]]></category>
		<category><![CDATA[Hospitality Properties Trust]]></category>
		<category><![CDATA[HPT]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[K]]></category>
		<category><![CDATA[Kellogg Company]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[OI]]></category>
		<category><![CDATA[Owens-Illinois Inc.]]></category>
		<category><![CDATA[SMG]]></category>
		<category><![CDATA[The Scotts Miracle-Gro Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76538</guid>
		<description><![CDATA[•    Share prices of Scotts Miracle-Gro Company (NYSE:SMG) dipped 6.02% after the company reduced its earnings estimate for the fiscal year 2011 •    Shares of Owens-Illinois (NYSE:OI) dropped 13.54% to close at $25.54 after the company said its second quarter earnings figures could fall due to a jump in manufacturing and delivery expenses •    Johnson &#38; Johnson (NYSE:JNJ) is reportedly pulling out of the drug-coated heart stent market because of continually declining sales. The global market for this segment is valued at $4 billion •    Analysts at Jefferies &#38; Co. initiated coverage on shares of General Mills, Inc. (NYSE:GIS) with &#8220;Hold&#8221; rating and a target price of $40 •    Analysts at Jefferies &#38; Co. initiated coverage on Shares of Kellogg (NYSE:K) with &#8220;Underperform&#8221; rating and also lowered the target price ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/ango-company-news-for-june-16-2011-corporate-summary/76538/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Unveils New DuraMax Catheter</title>
		<link>http://www.stockbloghub.com/2011/04/10/ango-angiodynamics-unveils-new-duramax-catheter/70970</link>
		<comments>http://www.stockbloghub.com/2011/04/10/ango-angiodynamics-unveils-new-duramax-catheter/70970#comments</comments>
		<pubDate>Mon, 11 Apr 2011 02:57:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70970</guid>
		<description><![CDATA[Therapeutic and diagnostic devices maker AngioDynamics (ANGO) has unveiled its new DuraMax stepped-tip chronic dialysis catheter in the U.S. The Queensbury, New York-based company has also launched the DuraMaxVP (VascPak) component kit designed for outpatient vascular access centers. AngioDynamics has begun shipping the DuraMax catheter, which leverages its proprietary Curved Tip catheter technology. The next generation catheter has been geared to facilitate easier insertion, higher blood flow and dialysis efficiency, thereby improving patient outcomes. Moreover, the catheter’s guidewire lumen, which positions the guidewire in the center of the leading edge of the catheter at the insertion site, significantly improves catheter placement vis-à-vis the existing options. Roughly 30%-50% of dialysis catheters are placed over a guidewire. AngioDynamics is a leading provider of therapeutic and diagnostic devices for treating peripheral vascular and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/10/ango-angiodynamics-unveils-new-duramax-catheter/70970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSDM) BSD Medical Setting up Sales Network</title>
		<link>http://www.stockbloghub.com/2010/12/25/bsdm-bsdm-setting-up-sales-network/63573</link>
		<comments>http://www.stockbloghub.com/2010/12/25/bsdm-bsdm-setting-up-sales-network/63573#comments</comments>
		<pubDate>Sun, 26 Dec 2010 04:13:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSD Medical Corporation]]></category>
		<category><![CDATA[BSDM]]></category>
		<category><![CDATA[BSX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63573</guid>
		<description><![CDATA[Cancer treatment systems maker BSD Medical Corp (BSDM) is in the final phase of implementing a dedicated global distribution network for its novel MicroThermX Microwave Ablation product line. In this regard, the company has strategized to use the network of specialty distribution firms, which markets products in the interventional radiology area. BSD Medical’s ablation products are targeted at this market. The company has already identified seven regional U.S. specialty distribution firms and plans to finalize distribution agreements with them over the coming weeks. These identified firms will supply as many as 60 sales professionals to promote and market the company’s MicroThermX products in the U.S. Initial training of these distributors is currently underway. Nationwide distribution coverage is expected within the first quarter of 2011. BSD Medical is leveraging the successful ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/25/bsdm-bsdm-setting-up-sales-network/63573/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Improves VenaCure Laser Vein Treatment</title>
		<link>http://www.stockbloghub.com/2010/09/16/ango-angiodynamics-improves-venacure-laser-vein-treatment/49900</link>
		<comments>http://www.stockbloghub.com/2010/09/16/ango-angiodynamics-improves-venacure-laser-vein-treatment/49900#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:23:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49900</guid>
		<description><![CDATA[Therapeutic and diagnostic devices maker AngioDynamics Inc. (ANGO) has expanded its VenaCure EVLT laser vein treatment with the launch of a new access kit, which will reduce both procedure time and steps for physicians using VenaCure’s NeverTouch laser fiber to treat varicose veins (abnormally swollen veins), a condition affecting more than 40 million Americans annually. The new access kit, which is equipped with a 0.018 inch long-access wire, trims the number of steps (from 8 to 4) to gain access for the VenaCure EVLT procedure. Besides, the faster procedure time enabled by the kit will lead to improved patient comfort. VenaCure EVLT, which includes DELTA series laser, procedure kits, accessories and a delivery system, offers patients a safe, minimally-invasive and effective option for treating the source of varicose veins while ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/ango-angiodynamics-improves-venacure-laser-vein-treatment/49900/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BCR) C.R. Bard Second Quarter 2010 Earnings Beat &#8211; Profit Climbs</title>
		<link>http://www.stockbloghub.com/2010/07/25/bcr-c-r-bard-second-quarter-2010-earnings-beat-profit-climbs/44494</link>
		<comments>http://www.stockbloghub.com/2010/07/25/bcr-c-r-bard-second-quarter-2010-earnings-beat-profit-climbs/44494#comments</comments>
		<pubDate>Mon, 26 Jul 2010 04:47:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44494</guid>
		<description><![CDATA[C. R. Bard (BCR) reported its second quarter results after the closing bell yesterday, with an adjusted (excluding acquisition-related items and write-downs) earnings per share of $1.39 surpassing the Zacks Consensus Estimate of $1.36 and the year-ago earnings of $1.23. Net income surged 11% year over year to $124.6 million (or $1.29 a share), driven by healthy performances across the company’s vascular and surgical specialties businesses. Revenues Revenues leapt 8% year over year to $673.9 million, ahead of the Zacks Consensus Estimate of $671 million, with growth registered across all major business segments. Barring a favorable foreign currency translation, sales increased 7% year over year. Geographically, U.S. sales (up 7%) contributed 69% to Bard’s total revenues while international sales (up 9%) accounted for the balance. Segment Results Revenues from the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/25/bcr-c-r-bard-second-quarter-2010-earnings-beat-profit-climbs/44494/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/05/17/ango-angiodynamics-analyst-maintains-neutral-rating/37237</link>
		<comments>http://www.stockbloghub.com/2010/05/17/ango-angiodynamics-analyst-maintains-neutral-rating/37237#comments</comments>
		<pubDate>Mon, 17 May 2010 15:21:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37237</guid>
		<description><![CDATA[We recently reiterated our ‘Neutral’ rating on AngioDynamics Inc. (ANGO) with a target price of $17 based on a P/E of 29.8x our fiscal 2011 EPS estimate of 57 cents. The company’s results for the third quarter fiscal 2010 were mixed. In the third quarter, AngioDynamics reported earnings per share of 13 cents, higher than the Zacks Consensus Estimate of 12 cents but lower than the year-ago figure of 15 cents. Total revenue in the third quarter increased 6% year over year to $52.2 million. Peripheral Vascular sales increased 8% year over year to $22.4 million. Growth was led by higher sales of VenaCure EVLT, Benephit targeted renal therapy systems, and Micro-Introducer kits. Oncology/Surgery sales increased 19% year over year to $13.7 million. Growth was due to higher demand for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/ango-angiodynamics-analyst-maintains-neutral-rating/37237/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Announces New Product</title>
		<link>http://www.stockbloghub.com/2010/05/11/ango-angiodynamics-announces-new-product/36809</link>
		<comments>http://www.stockbloghub.com/2010/05/11/ango-angiodynamics-announces-new-product/36809#comments</comments>
		<pubDate>Tue, 11 May 2010 21:45:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36809</guid>
		<description><![CDATA[AngioDynamics, Inc. (ANGO) recently launched its new product, Centros hemodialysis access catheter, in the United States. The new product uses a curved tip catheter technology and provides higher blood flow and lower recirculation. It has been tested that when Centros is placed in the lower portion of the superior vena cava, the curved tip of the product keeps the ports of the catheter away from the vein walls. This prevents clot formation and also stops the formation of fibrin sheathing in which a fibrous protein in the blood coats the catheter and compromises on its functioning. The Centros hemodialysis access catheter has superior features compared to other catheters available in the market. Preliminary studies suggest that the new product provides highly acceptable flow rates at modest negative pressure without deterioration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/11/ango-angiodynamics-announces-new-product/36809/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/04/01/ango-angiodynamics-beats-consensus-estimates/32644</link>
		<comments>http://www.stockbloghub.com/2010/04/01/ango-angiodynamics-beats-consensus-estimates/32644#comments</comments>
		<pubDate>Thu, 01 Apr 2010 21:33:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32644</guid>
		<description><![CDATA[AngioDynamics, Inc. (ANGO) recently reported third quarter fiscal 2010 earnings per share of 13 cents that beat the Zacks Consensus Estimate of 12 cents and the year-ago earnings of 8 cents. Sales Total revenues in the third quarter increased 6% year over year to $52.2 million. Peripheral Vascular sales increased 8% year over year to $22.4 million. Growth was led by higher sales of VenaCure EVLT, Benephit targeted renal therapy systems, and Micro-Introducer kits. Oncology/Surgery sales increased 19% year over year to $13.7 million. Growth was due to higher demand for RF ablation products and NanoKnife. Access revenue declined 6% year over year to $16.1 million. The decline can be attributed to lower average selling prices (ASPs) of certain Access products due to a competitive pricing environment, and delay in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/ango-angiodynamics-beats-consensus-estimates/32644/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Beats Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/06/ango-angiodynamics-beats-estimates/24335</link>
		<comments>http://www.stockbloghub.com/2010/01/06/ango-angiodynamics-beats-estimates/24335#comments</comments>
		<pubDate>Wed, 06 Jan 2010 23:56:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24335</guid>
		<description><![CDATA[AngioDynamics, Inc. (ANGO) reported second quarter fiscal 2010 earnings per share of 13 cents, beating the Zacks Consensus Estimate of 11 cents and the year-ago earnings of 12 cents. The company also reported an expansion in its top-line and raised the sales outlook for the entire year. Sales Net sales in the second quarter increased 10% year over year to $53.5 million. Growth was registered across all the business segments. Peripheral Vascular sales increased 6% year over year to $23.2 million. Growth was led by higher demand for the Benephit renal infusion system which AngioDynamics acquired from FlowMedica, and higher sales of EVLT Disposable Kit. Access sales increased 4% year over year to $16.7 million due to higher sales of PICC dialysis products. Oncology/Surgery sales increased 28% year over year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/ango-angiodynamics-beats-estimates/24335/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Launches Two New Products</title>
		<link>http://www.stockbloghub.com/2010/01/05/ango-angiodynamics-launches-two-new-products/24121</link>
		<comments>http://www.stockbloghub.com/2010/01/05/ango-angiodynamics-launches-two-new-products/24121#comments</comments>
		<pubDate>Tue, 05 Jan 2010 18:30:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24121</guid>
		<description><![CDATA[Recently, AngioDynamics (ANGO) expanded its product portfolio by launching two products ? the total abscession nephrostomy drainage catheter and the micro-introducer kits with a new stiffened introducer option. AngioDynamics completed the total abscession family of products by launching the nephrostomy drainage catheter.  The family of products Incorporatedlusive of general drains and a biliary drainage catheter, provides physicians and hospitals a full range of choice from a solitary source. The new drainage catheter is used in percutaneous nephrostomy drainage.  This minimally invasive procedure allows a physician to place the catheter through the skin in the back into the kidney thereby relieving pressure on the organ from a back-up of urine. The launch of a new family of micro-introducer kits by the company is also positive news for physicians. The micro-introducers make ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/ango-angiodynamics-launches-two-new-products/24121/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BCR) C.R. Bard Surpasses Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/22/bcr-c-r-bard-surpasses-consensus-estimates/18531</link>
		<comments>http://www.stockbloghub.com/2009/10/22/bcr-c-r-bard-surpasses-consensus-estimates/18531#comments</comments>
		<pubDate>Thu, 22 Oct 2009 22:25:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18531</guid>
		<description><![CDATA[C.R. Bard, Inc. (BCR) yesterday reported strong third quarter fiscal 2009 results after the market close. Earnings per share were $1.31, surpassing the Zacks Consensus Estimate of $1.27 and the year-ago earnings of $1.09. Sales Net sales in the quarter increased 3% year over year to $637.0 million. Excluding an unfavorable foreign currency translation (FX), net sales increased 6% year over year. On a geographic basis, U.S. sales contributed approximately 69.5% of total sales and increased 6% year over year. International sales declined 1% year over year. Growth was witnessed across all major business segments. Vascular sales increased 8% year over year to $173.6 million. Growth was led by strong demand for the disposable electrophysiology [EP], biopsy, peripheral PTA catheters and stent products. This was partly offset by lower surgical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/22/bcr-c-r-bard-surpasses-consensus-estimates/18531/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) AngioDynamics Outperforms Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/08/ango-angiodynamics-outperforms-estimates/17140</link>
		<comments>http://www.stockbloghub.com/2009/10/08/ango-angiodynamics-outperforms-estimates/17140#comments</comments>
		<pubDate>Thu, 08 Oct 2009 19:31:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17140</guid>
		<description><![CDATA[AngioDynamics, Inc. (ANGO) yesterday reported first quarter fiscal 2010 earnings per share of 9 cents, surpassing the Zacks Consensus Estimate of 8 cents. Earnings per share in the year-ago quarter also reached 9 cents. Sales Net sales in the reported quarter were $50.1 million Incorporatedreasing 13% year over year. The increase was across all the business segments. On a geographic basis, U.S. sales contributed approximately 90% of total sales and increased roughly 15% year over year. International sales were roughly flat year over year. Peripheral Vascular sales increased 14% year over year to $21.1 million. This was primarily due to the Benephit renal infusion system and Diomed acquisitions. Access sales increased 3% year over year to $16.2 million. Oncology/Surgery sales increased 25% year over year to $12.8 million. Margins Gross ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/08/ango-angiodynamics-outperforms-estimates/17140/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

